首页 | 本学科首页   官方微博 | 高级检索  
检索        

北京地区46家医院2008-2010年抗良性前列腺增生药利用分析
引用本文:任伟,白利,张石革,甄健存.北京地区46家医院2008-2010年抗良性前列腺增生药利用分析[J].中国药房,2012(22):2027-2030.
作者姓名:任伟  白利  张石革  甄健存
作者单位:北京积水潭医院药剂科/北京大学第四临床医学院,北京100035
摘    要:目的:评价北京地区医院抗良性前列腺增生(BPH)药的利用情况。方法:采用回顾性方法,对北京地区46家医院2008-2010年抗BPH药的用药频度(DDDs)、日均费用(DDC)及药品销售金额排序(B)/DDDs排序(A)值等进行统计、分析。结果:该地区医院抗BPH药销售金额年均增长率约为13.82%;单药销售金额排序及DDDs排序列前5位的药品3年基本一致,均为非那雄胺、坦洛新、多沙唑嗪、特拉唑嗪与普适泰,其销售金额年均增长率分别为17.45%、17.35%、9.69%、9.43%、16.90%;排6~10位药品的市场份额由2008年的11.12%下降至2010的9.04%;抗雄性激素类药与α1受体拮抗药在分类金额汇总与DDDs汇总上于2010分别达98.97%和97.14%;3年中各药的DDC变化不大;占市场份额最高的非那雄胺与坦洛新的B/A均为1。结论:北京地区医院抗BPH药的应用情况呈明显的上升趋势。临床应用以抗雄性激素类药与α1受体拮抗药为主,二者联用有协同作用,但会使治疗成本增加;植物制剂无明显的不良反应,效果显著且价格相对低廉,应加大研发力度,以便进一步推动其临床应用。

关 键 词:抗良性前列腺增生药  北京地区  利用分析

Analysis of the Utilization of Drugs against Benign Prostatic Hyperplasia in 46 Hospitals of Beijing Area from 2008 to 2010
REN Wei,BAI Li,ZHANG Shi-ge,ZHEN Jian-cun.Analysis of the Utilization of Drugs against Benign Prostatic Hyperplasia in 46 Hospitals of Beijing Area from 2008 to 2010[J].China Pharmacy,2012(22):2027-2030.
Authors:REN Wei  BAI Li  ZHANG Shi-ge  ZHEN Jian-cun
Institution:(Dept.of Pharmacy,Beijing Jishuitan Hospital&The Forth Clinical Medical College of Peking University,Beijing 100035,China)
Abstract:OBJECTIVE:To evaluate the utilization of the drugs against benign prostatic hyperplasia(BPH) in hospitals of Beijing area.METHODS:By retrospective study,the utilization of the drugs against BPH in 46 hospitals of Beijing area during the period of 2008-2010 was analyzed statistically in respect of DDDs,DDC,the rank of consumption sum(B) and the rank of DDDs(A),etc.RESULTS:The average annual growth rate of consumption sum of the drugs against BPH in hospitals at this area was about 13.82%.Finasteride,tamsulosin,doxazosin,terazosin,prostate took the first five places on the lists of consumption sum and DDDs of the drugs against BPH over past three years,with an average annual growth rate of consumption sum of 17.45%,17.35%,9.69%,9.43%,16.90%,respectively.The total market share for the drugs ranking of six to ten decreased from 11.12% in 2008 to 9.04% in 2010.Amount and DDDs of anti-androgenic hormone drugs and α1 receptor blocking reached 98.97% and 97.14% in 2010.DDC changed little in three years,and the top two drugs in the list of market share were finasteride and tamsulosin with B/A of 1,CONCLUSIONS:The consumption sum of the drugs against BPH in Beijing area shows an obvious increase trend.Anti-androgenic hormone drugs and α1 receptor blocking were mainly used in the clinic,and the combination of above two drugs could make synergistic action with the increase of treatment cost.Herbal medicines have good therapeutic effect and relatively low price without significant adverse reactions.More research efforts should be made to further promote the clinical application of herbal medicines.
Keywords:Drugs against benign prostatic hyperplasia  Beijing area  Utilization analysis
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号